CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021		$ 46	$ 368,852	$ (374,934)	$ (6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Issuance of common stock under the Sales Agreement, net		$ 3	2,638		2,641
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	2,395,823
Share-based compensation related to stock options			293		293
Share-based compensation related to restricted stock awards			831		831
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net income (loss) for the period				(7,620)	(7,620)
Ending balance at Jun. 30, 2022		$ 49	372,616	(382,554)	(9,889)
Ending balance (in shares) at Jun. 30, 2022	[1]	48,712,952
Beginning balance at Mar. 31, 2022		$ 46	369,688	(377,220)	(7,486)
Beginning balance (in shares) at Mar. 31, 2022	[1]	46,316,129
Issuance of common stock under the Sales Agreement, net		$ 3	2,638		2,641
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	2,395,823
Share-based compensation related to stock options			144		144
Share-based compensation related to restricted stock awards			144		144
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net income (loss) for the period				(5,334)	(5,334)
Ending balance at Jun. 30, 2022		$ 49	372,616	(382,554)	(9,889)
Ending balance (in shares) at Jun. 30, 2022	[1]	48,712,952
Beginning balance at Dec. 31, 2022		$ 54	379,167	(389,861)	(10,640)
Beginning balance (in shares) at Dec. 31, 2022	[1]	53,790,167
Issuance of common stock under the Sales Agreement, net		$ 13	23,941		23,954
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	12,560,150
Convertible notes conversions		$ 5	7,778		7,783
Convertible notes conversions (in shares)	[1]	4,691,623
Share-based compensation related to stock options			812		812
Share-based compensation related to restricted stock awards			172		172
Exercise of warrants			712		712
Exercise of warrants (in shares)	[1]	538,822
Net income (loss) for the period				16,208	16,208
Ending balance at Jun. 30, 2023		$ 72	412,582	(373,653)	39,001
Ending balance (in shares) at Jun. 30, 2023	[1]	71,580,762
Beginning balance at Mar. 31, 2023		$ 62	393,938	(392,992)	1,008
Beginning balance (in shares) at Mar. 31, 2023	[1]	62,002,649
Issuance of common stock under the Sales Agreement, net		$ 5	9,716		9,721
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	4,347,668
Convertible notes conversions		$ 5	7,778		7,783
Convertible notes conversions (in shares)	[1]	4,691,623
Share-based compensation related to stock options			359		359
Share-based compensation related to restricted stock awards			79		79
Exercise of warrants			712		712
Exercise of warrants (in shares)	[1]	538,822
Net income (loss) for the period				19,339	19,339
Ending balance at Jun. 30, 2023		$ 72	$ 412,582	$ (373,653)	$ 39,001
Ending balance (in shares) at Jun. 30, 2023	[1]	71,580,762

[1] Common stock, $0.001 par value; Authorized – as of June 30, 2023 and 2022 – 144,000,000 shares.